Gamma-vinyl GABA, an irreversible inhibitor of GABA transaminase, alters the acquisition and expression of cocaine-induced sensitization in male rats

被引:33
作者
Gardner, EL
Schiffer, WK
Horan, BA
Highfield, D
Dewey, SL
Brodie, JD
Ashby, CR
机构
[1] St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Hlth Sci, Jamaica, NY 11439 USA
[2] NIDA, Intramural Res Program, NIH, Baltimore, MD 21224 USA
[3] Brookhaven Natl Lab, Dept Chem, Upton, NY 11973 USA
[4] Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA
[5] NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA
关键词
gamma-vinyl GABA; cocaine; sensitization; locomotion; stereotypy;
D O I
10.1002/syn.10138
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We examined the effect of (+/-)-gamma-vinyl GABA (GVG, Vigabatrin), an irreversible inhibitor of the enzyme GABA transaminase, on the acquisition and expression of cocaine-induced sensitization in albino male Sprague-Dawley rats. Animals received a single injection of 1 ml/kg i.p. of 0.9% saline or 15 mg/kg i.p. of (-)-cocaine and locomotor activity was assessed using automated locomotor cages and stereotyped behaviors were scored using a 4-point rating scale (Day 1). Subsequently, animals were given 15 mg/kg i.p. of cocaine every 48 h in their home cage for 1 week (Days 3, 5, and 7) and then given no treatment for 1 week. A challenge injection of 15 mg/kg i.p. of cocaine, but not vehicle, produced a significant increase in locomotor activity and stereotyped behaviors on Day 15 compared to animals that received cocaine on Day 1. Administration of 75 mg/kg i.p. of GVG 2.5 h before the cocaine injections did not significantly alter the acquisition of cocaine-induced locomotor sensitization. However, 150 mg/kg i.p. of GVG significantly attenuated the acquisition of cocaine-induced locomotor sensitization. Administration of 150 mg/kg i.p. of GVG 2.5 h before the cocaine challenge injection on Day 15 significantly attenuated the expression of cocaine-induced locomotor sensitization. Acquisition and expression of cocaine-induced sensitization of stereotypy was also significantly attenuated by 150 mg/kg i.p. of GVG. Since sensitization may be one of the factors involved in relapse to drug use, the present results, in combination with previous findings that GVG blocks the rewarding and incentive motivating effects of cocaine, suggest that GVG might prove useful in the treatment of cocaine addiction. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:240 / 250
页数:11
相关论文
共 82 条
[1]  
[Anonymous], 1997, ANOVA BASICS APPL ST, DOI DOI 10.1201/B15236
[2]  
ASHBY CR, 1999, SYNAPSE, V32, P51
[3]   Selective sensitization to the psychosis-inducing effects of cocaine: A possible marker for addiction relapse vulnerability? [J].
Bartlett, E ;
Hallin, A ;
Chapman, B ;
Angrist, B .
NEUROPSYCHOPHARMACOLOGY, 1997, 16 (01) :77-82
[4]   What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? [J].
Berridge, KC ;
Robinson, TE .
BRAIN RESEARCH REVIEWS, 1998, 28 (03) :309-369
[5]  
Bertrand S, 2001, J PHARMACOL EXP THER, V298, P15
[6]   RELATIONSHIP BETWEEN GABA CONCENTRATIONS IN BRAIN AND CEREBROSPINAL-FLUID [J].
BOHLEN, P ;
HUOT, S ;
PALFREYMAN, MG .
BRAIN RESEARCH, 1979, 167 (02) :297-305
[7]   Repeated cocaine alters glutamate receptor subunit levels in the nucleus accumbens and ventral tegmental area of rats that develop behavioral sensitization [J].
Churchill, L ;
Swanson, CJ ;
Urbina, M ;
Kalivas, PW .
JOURNAL OF NEUROCHEMISTRY, 1999, 72 (06) :2397-2403
[8]   CHRONIC COCAINE ENHANCES SEROTONIN AUTOREGULATION AND SEROTONIN UPTAKE BINDING [J].
CUNNINGHAM, KA ;
PARIS, JM ;
GOEDERS, NE .
SYNAPSE, 1992, 11 (02) :112-123
[9]   SEROTONIN NEUROTRANSMISSION IN COCAINE SENSITIZATION [J].
CUNNINGHAM, KA ;
PARIS, JM ;
GOEDERS, NE .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1992, 654 :117-127
[10]   Relapse to cocaine- and heroin-seeking behavior mediated by dopamine D2 receptors is time-dependent and associated with behavioral sensitization [J].
De Vries, TJ ;
Schoffelmeer, ANM ;
Binnekade, R ;
Raaso, H ;
Vanderschuren, LJMJ .
NEUROPSYCHOPHARMACOLOGY, 2002, 26 (01) :18-26